WuXi AppTec (HKG:2359) expects a net attributable profit of 19.2 billion yuan for the year 2025, up 103% from 9.45 billion yuan a year prior, according to a Monday Hong Kong bourse filing.
The drug research company attributed the forecast to an investment gain from the sale of interest in WuXi XDC Cayman, as well as enhanced capabilities and capacity, optimized production processes, and improved operating efficiency.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments